KCNJ8 and cardiovascular disorder: Iptakalim, 2, 3-dimethyl-N-(1-methylethyl)-2-butanamine hydrochloride, has been established as a novel selective KATP opener with preferential activation of the SUR2B/Kir6.1 subtypes of KATP[22] and shown to be a promising drug for treatment of cardiovascular disease.